lly glp 1 drug Eli Lilly and phase results 2 on their dual GIP/GLP1 receptor agonist LY3298176 Eli Lilly Hits $1.01 Trillion

With the development of new anti-obesity medications, we hope this will encourage more active medical interventions for patients with severe obesity who have faced limitations in weight management despite lifestyle interventions." Lilly Korea Executive Director of Diabetes Business Unit and CMO Kim Kye-won also said, Despite extensive research and substantial scientific evidence, obesity patients in Korea still experience stigma and prejudice related to their weight. This can hinder patients' efforts to improve their health and negatively impact the quality of treatment they receive, Kim added

Thus, this drives the market growth

While further behind alcohol and nicotine research, preliminary studies are examining whether GLP-1 agonists could complement existing treatments like buprenorphine and naltrexone for opioid use disorder

Tan HC et al

PKA induction from native GLP-1 phosphorylates a key serine residue in NOS [40]